30.62
price down icon8.71%   -2.92
pre-market  Vorhandelsmarkt:  29.72   -0.90   -2.94%
loading
Schlusskurs vom Vortag:
$33.54
Offen:
$33.42
24-Stunden-Volumen:
2.20M
Relative Volume:
2.28
Marktkapitalisierung:
$2.85B
Einnahmen:
$4.72M
Nettoeinkommen (Verlust:
$-277.91M
KGV:
-8.2091
EPS:
-3.73
Netto-Cashflow:
$-203.56M
1W Leistung:
-12.69%
1M Leistung:
-14.42%
6M Leistung:
-41.02%
1J Leistung:
-34.19%
1-Tages-Spanne:
Value
$29.18
$33.42
1-Wochen-Bereich:
Value
$29.18
$35.26
52-Wochen-Spanne:
Value
$29.18
$62.53

Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile

Name
Firmenname
Crinetics Pharmaceuticals Inc
Name
Telefon
858-450-6464
Name
Adresse
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
Name
Mitarbeiter
437
Name
Twitter
@Crinetics
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
CRNX's Discussions on Twitter

Vergleichen Sie CRNX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CRNX
Crinetics Pharmaceuticals Inc
30.62 2.85B 4.72M -277.91M -203.56M -3.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-25 Eingeleitet Stifel Buy
2025-02-11 Eingeleitet TD Cowen Buy
2025-02-04 Eingeleitet Wolfe Research Peer Perform
2025-01-22 Hochstufung Jefferies Hold → Buy
2024-03-06 Eingeleitet Citigroup Buy
2024-01-16 Eingeleitet Morgan Stanley Overweight
2023-12-21 Eingeleitet Jefferies Hold
2023-11-20 Fortgesetzt JP Morgan Overweight
2023-10-24 Fortgesetzt Cantor Fitzgerald Overweight
2023-08-31 Eingeleitet Oppenheimer Outperform
2023-04-24 Eingeleitet Piper Sandler Overweight
2023-03-30 Eingeleitet Robert W. Baird Outperform
2021-11-30 Eingeleitet JMP Securities Mkt Outperform
2021-11-23 Eingeleitet Evercore ISI Outperform
2021-06-18 Hochstufung JP Morgan Neutral → Overweight
2019-12-23 Eingeleitet ROTH Capital Buy
2019-02-14 Eingeleitet H.C. Wainwright Buy
2018-08-13 Eingeleitet JP Morgan Neutral
2018-08-13 Eingeleitet Leerink Partners Outperform
2018-08-13 Eingeleitet Piper Jaffray Overweight
Alle ansehen

Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten

pulisher
Mar 27, 2025

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation Of Marketing Authorization Application (MAA) And Orphan Drug Designation (ODD) For Paltusotine In Acromegaly - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough: First Oral Acromegaly Drug Hits Major EU Milestone with Dual Regulatory Wins - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Crinetics Pharmaceuticals (NASDAQ:CRNX) Now Covered by Stifel Nicolaus - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

Stifel Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Buy Recommendation - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target - Marketscreener.com

Mar 25, 2025
pulisher
Mar 24, 2025

Cushing's Syndrome Pipeline 2025: Therapies, MOA Insights, - openPR.com

Mar 24, 2025
pulisher
Mar 24, 2025

(CRNX) Trading Report - Stock Traders Daily

Mar 24, 2025
pulisher
Mar 24, 2025

Connor Clark & Lunn Investment Management Ltd. Sells 13,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

Proficio Capital Partners LLC Purchases Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock By Investing.com - Investing.com Australia

Mar 22, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Stock: Executives Sell Shares Amid Analyst Optimism - sharewise.com

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 By Investing.com - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock - Investing.com

Mar 21, 2025
pulisher
Mar 19, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Mar 19, 2025
pulisher
Mar 16, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Charles Schwab Investment Management Inc. - Defense World

Mar 16, 2025
pulisher
Mar 14, 2025

US Bancorp DE Sells 5,176 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Where are the Opportunities in (CRNX) - Stock Traders Daily

Mar 13, 2025
pulisher
Mar 13, 2025

Will Crinetics Pharma's Upcoming Events Drive Stock Momentum? - RTTNews

Mar 13, 2025
pulisher
Mar 12, 2025

Bank of New York Mellon Corp Has $17.63 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Mar 12, 2025
pulisher
Mar 10, 2025

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Crinetics Pharmaceuticals Grants Stock Options and RSUs to New Employees Under 2021 Inducement Plan - Nasdaq

Mar 10, 2025
pulisher
Mar 10, 2025

Crinetics Awards Major Stock Grants to 17 New Hires Including Executive - Stock Titan

Mar 10, 2025
pulisher
Mar 09, 2025

Proficio Capital Partners LLC Acquires Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Mar 09, 2025
pulisher
Mar 07, 2025

Promising Pipeline and Strategic Initiatives Drive Buy Rating for Crinetics Pharmaceuticals - TipRanks

Mar 07, 2025
pulisher
Mar 04, 2025

Principal Financial Group Inc. Boosts Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Crinetics Pharma’s Earnings Call: Progress Amid Challenges - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2024 Earnings Call Transcript - MSN

Mar 03, 2025
pulisher
Mar 02, 2025

Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Up 6.1% on Better-Than-Expected Earnings - Defense World

Mar 02, 2025
pulisher
Mar 01, 2025

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance UK

Mar 01, 2025
pulisher
Mar 01, 2025

Cantor Fitzgerald lifts Crinetics stock target to $100 By Investing.com - Investing.com Canada

Mar 01, 2025
pulisher
Mar 01, 2025

Crinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 1-Year LowHere's What Happened - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Crinetics Pharmaceuticals (NASDAQ:CRNX) Announces Earnings Results - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Crinetics Pharmaceuticals: Promising Developments and Strategic Initiatives Underpin Buy Rating - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Crinetics price target lowered to $91 from $92 at Citizens JMP - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Crinetics Pharmaceuticals: Promising Future with Paltusotine Launch and Robust Pipeline Development - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Decoding Crinetics Pharmaceuticals Inc (CRNX): A Strategic SWOT Insight - GuruFocus.com

Feb 28, 2025
pulisher
Feb 28, 2025

Crinetics Pharmaceuticals: Positioned for Growth with Promising Drug Pipeline and Strong Financials - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

Crinetics Pharmaceuticals: Financial Results and Future Plans - TipRanks

Feb 28, 2025
pulisher
Feb 27, 2025

Crinetics Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Crinetics Pharmaceuticals Q4 Net Loss Narrows -February 27, 2025 at 05:15 pm EST - Marketscreener.com

Feb 27, 2025

Finanzdaten der Crinetics Pharmaceuticals Inc-Aktie (CRNX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
Kapitalisierung:     |  Volumen (24h):